Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Roseomonas mucosa + cardamom seeds
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Classical Binding Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
Roseomonas mucosa + cardamom seeds is a topical live biotherapeutic product (LBP) developed for the treatment of atopic dermatitis (AD). The formulation consists of the specific bacterial strain *Roseomonas mucosa* RSM2015, originally isolated and characterized at the NIAID's Laboratory of Clinical Immunology and Microbiology, combined with ground cardamom seeds in a sucrose solution. *R. mucosa* acts by colonizing the skin and producing protective lipids, such as ceramides and sphingolipids, which restore the epithelial barrier and modulate inflammatory responses. The addition of cardamom seeds is intended to provide an anti-pruritic effect to reduce itching. The product is currently being evaluated in Phase 2b clinical trials and is marketed as an over-the-counter topical probiotic under the brand name Defensin.
- Brand names
- Defensin
- Other names
- Roseomonas mucosa strain RSM2015Skinesa Defensintopical Roseomonas mucosa
02
Targets
TNFR2 (Tumor necrosis factor receptor superfamily member 1B)
Beyond the preview
Go deeper on Roseomonas mucosa + cardamom seeds.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Roseomonas mucosa + cardamom seeds.